Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. - ROEverified

0LB2.L

Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research, development, and market introduction of therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed medications addresses a range of CNS conditions. These include Trokendi XR, an extended-release formulation of topiramate used for managing epilepsy and preventing migraine headaches, and Oxtellar XR, an extended-release oxcarbazepine prescribed as a standalone treatment for partial-onset epileptic seizures in individuals aged 6 to 17 and adults. Another key offering is Qelbree, a selective norepinephrine reuptake inhibitor specifically designed for pediatric patie...[Read more]

Industry

Drug Manufacturers - Specialty & Generic

IPO Date

2018-01-29

Stock Exchange

LSE

Ticker

0LB2.L

The ROE as of September 2026 (TTM) for Supernus Pharmaceuticals, Inc. (0LB2.L) is -10.42%

According to Supernus Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -10.42%. This represents a change of 294.66% compared to the average of -2.64% of the last 4 quarters.

Supernus Pharmaceuticals, Inc. (0LB2.L) Historical ROE (quarterly & annually)

How has 0LB2.L ROE performed in the past?

The mean historical ROE of Supernus Pharmaceuticals, Inc. over the last ten years is 14.66%. The current -10.42% ROE has changed -171.08% with respect to the historical average. Over the past ten years (40 quarters), 0LB2.L's ROE was at its highest in in the September 2016 quarter at 35.66%. The ROE was at its lowest in in the June 2026 quarter at -5.66%.

Quarterly (TTM)
Annual

Average

14.66%

Median

12.09%

Minimum

-3.63%

Maximum

47.57%

Supernus Pharmaceuticals, Inc. (0LB2.L) ROE by Quarter and Year

Discovering the peaks and valleys of Supernus Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 4.89%

Maximum Annual ROE = 47.57%

Minimum Annual Increase = -150.91%

Minimum Annual ROE = -3.63%

Quarterly (TTM)
Annual
YearROEChange
2025-3.63%-150.91%
20247.13%4.89%
20230.14%-97.92%
20226.85%4.62%
20216.55%-61.58%
202017.04%-10.24%
201918.99%-22.50%
201824.50%14.40%
201721.42%-54.98%
201647.57%303.47%

Supernus Pharmaceuticals, Inc. (0LB2.L) Average ROE

How has 0LB2.L ROE performed in the past?

The current ROE of Supernus Pharmaceuticals, Inc. (0LB2.L) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

1.21%

5-year avg

3.41%

10-year avg

14.66%

Supernus Pharmaceuticals, Inc. (0LB2.L) ROE vs. Peers

How is 0LB2.L’s ROE compared to its peers?

Supernus Pharmaceuticals, Inc.’s ROE is greater than Perrigo Co. Plc (-55.97%), greater than Amicus Therapeutics, Inc. (-12.02%), greater than Agios Pharmaceuticals, Inc. (-35.67%), greater than Sarepta Therapeutics, Inc. (-9.96%), greater than Viking Therapeutics, Inc. (-94.56%), greater than DENTSPLY SIRONA Inc. (-39.81%), greater than uniQure N.V. (-111.96%), greater than Dynavax Technologies Corporation (-9.71%), greater than Intellia Therapeutics, Inc. (-57.79%), greater than OPKO Health, Inc. (-5.88%),

Build a custom stock screener for Supernus Pharmaceuticals, Inc. (0LB2.L) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Supernus Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Supernus Pharmaceuticals, Inc. (0LB2.L) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Supernus Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Supernus Pharmaceuticals, Inc.'s ROE?

How is the ROE calculated for Supernus Pharmaceuticals, Inc. (0LB2.L)?

What is the highest ROE for Supernus Pharmaceuticals, Inc. (0LB2.L)?

What is the 3-year average ROE for Supernus Pharmaceuticals, Inc. (0LB2.L)?

What is the 5-year average ROE for Supernus Pharmaceuticals, Inc. (0LB2.L)?

How does the current ROE for Supernus Pharmaceuticals, Inc. (0LB2.L) compare to its historical average?